Drug found to delay Type-1 diabetes by 2 years

Henrietta Brewer
June 13, 2019

A monoclonal antibody called teplizumab has been shown to delay the onset of type 1 diabetes for as long as two years.

According to the data collected, in the group of people receiving Teplizumab, type 1 diabetes developed one year later than those who received placebo: 7% of people who received the experimental drug were diagnosed with diabetes in the first year after starting therapy, while as in the placebo group, this figure was 44%.

When 41% of the participants' developed Type-1 diabetes, preliminary in the placebo group, the effects of the drugs were at a higher rate when it was given in the first year.

Relatives of patients with type 1 diabetes (T1D) are at an increased risk for developing the disease themselves.

The trial was conducted by Type 1 Diabetes Trialnet, which researches strategies to delay or prevent T1D.


At the end of the trial, the investigators determined that individuals in the treatment group who developed type 1 diabetes did so an average of two years later than those who received the placebo. If you're taking vitamin D and expecting it to lower your risk of getting type 2 diabetes when you get older, it's time to lower your expectations.

A delay in diagnosis also means two fewer years with the disease.

A new study, the largest of its kind, has found that taking 4000 global units (IU) per day, which is on the upper limit of the recommended intake, may double the amount of vitamin D in the blood but it gives most people roughly the same chance of developing blood sugar problems as people who don't take the vitamin.

"You have to talk to someone who has diabetes", he said.

"But it's particularly an issue for children, who represent about three-quarters of the participants in our study", he stated. The researchers recruited 76 patients between the ages of 8 and 49 who have relatives diagnosed with type 1 diabetes.


Type 2 diabetes is a condition where the insulin your pancreas makes can't work properly, or your pancreas can't make enough insulin. "Having an understanding of diabetes is key to helping people live better, and that's why we are celebrating Diabetes Week all week and by sharing the Diabetes UK "Five Facts of Diabetes" to help reach as many people as possible".

All included individuals had dysglycemia prior to the study, marked by a fasting glucose between 110-125 mg/dL, a 2-hour post-prandial plasma glucose ≥140-200 mg/dL, or an intervening postprandial glucose levels 200 mg/dL at two occasions. It is the immune system's attack on the beta cells that characterises type 1 diabetes. This intravenous infusion was given as a 51 µgram/m of body-surface area on at day 0.

Teplizumab was associated with some adverse events (AE), with 112 events occurring in the study arm versus 23 events reported with placebo. Participants who responded to teplizumab tended to have certain autoantibodies and other immune system characteristics. But we also want to prevent this condition ever developing in those at risk.

Shares in the USA biotech rose 217% to $13.79 thanks to the phase 2 trial in 76 patients at risk of developing Type 1 diabetes (T1D) who were given PRV-031 significantly delayed the onset and diagnosis of Type 1 diabetes compared to placebo, by a median of 2 years in children and adults considered to be at high risk.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.


Herold disclosed support from the NIH, Juvenile Diabetes Research Foundation; relevant relationships with Provention Bio, Tiziana Life Sciences, Bristol Meyers Squibb, Eli Lilly, Merck, Forkhead, Semma, Toleron; and holding a patent for β-cell death assay.

Other reports by iNewsToday

FOLLOW OUR NEWSPAPER